Abstract
Background Terazosin and closely related α1-adrenergic receptor antagonists (doxazosin and alfuzosin; TZ/DZ/AZ) enhance glycolysis and reduce neurodeneration in animal models. Observational evidence in humans from several databases support this finding; however, a recent study has suggested that tamsulosin, the comparator medication, increases risk of Parkinson’s disease. We consider a different comparison group of men taking 5α-reductase inhibitors as a new, independent comparison allowing us to both obtain new estimates of the association between TZ/DZ/AZ and Parkinson’s disease outcomes and validate tamsulosin as an active comparator.
Methods Using the Truven Health Analytics Marketscan database, we identified men without Parkinson’s disease, newly started on TZ/DZ/AZ, tamsulosin, or 5α-reductase inhibitors. We followed these matched cohorts to compare the hazard of developing Parkinson’s disease.
Results We found that men taking TZ/DZ/AZ had a lower hazard of Parkinson’s disease than men taking tamsulosin (HR=0.72, 95% CI: 0.66-0.78, n=239,946) and lower than men taking a 5α-reductase inhibitors (HR=0.81, 95% CI: 0.72-0.92, n=129,320). The hazard for men taking tamsulosin was not statistically significantly different than for men taking 5α-reductase inhibitors (HR=1.10, 95% CI: 1.00-1.22, n=157,490).
Conclusions These data suggest that men using TZ/DZ/AZ have a lower risk of developing Parkinson’s disease than those using tamsulosin or 5α-reductase inhibitors while users of tamsulosin and 5α-reductase inhibitors have relatively similar survival functions.
Competing Interest Statement
The University of Iowa Research Foundation has filed patents for intellectual property related to use of terazosin and related compounds for neurodegeneration. MJW is a co-founder of Shandong Bangentai Biomedical Technology Group Co., Ltd in Jinan, China. This company is working to develop treatments for people with PD. The authors declare no other competing interests.
Funding Statement
The Truven database was provided by the University of Iowa. Dr. Simmering was supported by a faculty fellowship through the Iowa Neuroscience Institute. Dr. Welsh is an HHMI Investigator. Dr. Narayanan is supported by the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Iowa IRB waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: The University of Iowa Research Foundation has filed patents for intellectual property related to use of terazosin and related compounds for neurodegeneration. MJW is a co-founder of Shandong Bangentai Biomedical Technology Group Co., Ltd in Jinan, China. This company is working to develop treatments for people with PD. The authors declare no other competing interests.
Funding: The Truven database was provided by the University of Iowa. Dr. Simmering was supported by a faculty fellowship through the Iowa Neuroscience Institute. Dr. Welsh is an HHMI Investigator. Dr. Narayanan is supported by the NIH.
Data Availability
Data is used under license from Truven Analytics/IBM Health.
